SAN FRANCISCO--(BUSINESS WIRE)--AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that David A. Larson, M.D., PhD, was awarded the 2016 Leksell Gamma Knife Society Pioneer Award. The Leksell Gamma Knife Society was established in 1989 to provide a forum for Gamma Knife users to share information, experiences, clinical techniques and advanced scientific research in their quest to non-invasively treat an expanding number of brain disorders. The Leksell Gamma Knife Society Pioneers in Radiosurgery Award is bestowed upon researchers who have consistently pioneered new approaches and methods that enhance the results of Gamma Knife surgery.
AMS Chairman and Chief Executive Officer Ernest A. Bates, M.D., said, "Dr. David Larson is widely recognized for seminal contributions to radiosurgery. He was among the first to suggest that radiosurgery alone could be adequate for the treatment of brain metastases. He did so at a time when this concept was very controversial, even among his own peers. His many clinical and research contributions over the past 25 years contributed significantly to the widespread adoption of radiosurgery, and the Gamma Knife in particular, by the radiation oncology community. This well-earned Pioneer Award recognizes Dr. Larson's lifetime of accomplishments and his dramatic impact on the field of radiation oncology."
Dr. Larson, who was elected to the AMS Board in 2011, is professor emeritus of Radiation Oncology at the University of California, San Francisco. Dr. Larson is also currently employed as a radiation oncology physician at the Washington Hospital Healthcare System Gamma Knife Program. He is an internationally recognized authority on brain tumors and on central nervous system and body radiosurgery, intensity modified radiotherapy, and highly conformal radiotherapy. He holds a PhD in High Energy Physics from the University of Chicago and an MD from the University of Miami School of Medicine. He completed his medical internship at the University of California, San Francisco and his radiation oncology residency training at Harvard Medical School, where he also served as attending physician and instructor. Dr. Larson has been a member of the UCSF academic faculty since 1986, leading to joint professorial appointments in the Departments of Radiation Oncology and Neurosurgery. He has authored more than 200 scientific papers, reviews, and book chapters. He was elected by his peers to the presidency of numerous professional societies, including the American Society for Radiation Oncology (ASTRO), the Northern California Radiation Oncology Society (NCROS), and the International Stereotactic Radiosurgery Society (ISRS). He is a Fellow in the American College of Radiation Oncology (FACRO), the American College of Radiology (FACR), and the American Society for Radiology Oncology (FASTRO).
American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers proton therapy, the latest IGRT and IMRT systems, as well as its proprietary Operating Room for the 21st CenturySM concept. AMS owns a common stock investment in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System.
Safe Harbor Statement
This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services, which involve risks and uncertainties including, but not limited to, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of investing in Mevion Medical Systems, Inc., and the risks of the timing, financing, and operations of the Company’s proton therapy business. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2015, its quarterly report on Form 10-Q for the three months ended March 31, 2016, and the definitive Proxy Statement for the Annual Meeting of Shareholders to be held on June 21, 2016.